Literature DB >> 23315502

The IL-33/ST2 axis: yet another therapeutic target in inflammatory bowel disease?

Azucena Salas.   

Abstract

Entities:  

Keywords:  Cytokines; IBD

Mesh：

Substances：

Year:  2013        PMID： 23315502     DOI： 10.1136/gutjnl-2012-303920

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  10 in total

1.  Inhibition of matrix metalloproteinase-9 by a barbiturate-nitrate hybrid ameliorates dextran sulphate sodium-induced colitis: effect on inflammation-related genes.

Authors:  Shane O'Sullivan; Jun Wang; Maria T Pigott; Neil Docherty; Noreen Boyle; Samuel Kana Lis; John F Gilmer; Carlos Medina
Journal:  Br J Pharmacol       Date:  2017-02-24       Impact factor: 8.739

2.  From proteomics to discovery of first-in-class ST2 inhibitors active in vivo.

Authors:  Abdulraouf M Ramadan; Etienne Daguindau; Jason C Rech; Krishnapriya Chinnaswamy; Jilu Zhang; Greg L Hura; Brad Griesenauer; Zachary Bolten; Aaron Robida; Martha Larsen; Jeanne A Stuckey; Chao-Yie Yang; Sophie Paczesny
Journal:  JCI Insight       Date:  2018-07-26

Review 3.  Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications.

Authors:  R K Boyapati; A G Rossi; J Satsangi; G-T Ho
Journal:  Mucosal Immunol       Date:  2016-03-02       Impact factor: 7.313

4.  Genetic deletion of IL-25 (IL-17E) confers resistance to dextran sulfate sodium-induced colitis in mice.

Authors:  An-Jiang Wang; Allen Smith; Yanfei Li; Joseph F Urban; Thirumalai R Ramalingam; Thomas A Wynn; Nonghua Lu; Terez Shea-Donohue; Zhonghan Yang; Aiping Zhao
Journal:  Cell Biosci       Date:  2014-11-26       Impact factor: 7.133

Review 5.  Interleukin-33: Its Emerging Role in Allergic Diseases.

Authors:  Wen Ding; Gui-Lin Zou; Wei Zhang; Xing-Ning Lai; Hou-Wen Chen; Li-Xia Xiong
Journal:  Molecules       Date:  2018-07-09       Impact factor: 4.411

Review 6.  IL33: Roles in Allergic Inflammation and Therapeutic Perspectives.

Authors:  Ben C L Chan; Christopher W K Lam; Lai-Shan Tam; Chun K Wong
Journal:  Front Immunol       Date:  2019-03-04       Impact factor: 7.561

7.  IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice.

Authors:  R Guabiraba; A G Besnard; G B Menezes; T Secher; M S Jabir; S S Amaral; H Braun; R C P Lima-Junior; R A Ribeiro; F Q Cunha; M M Teixeira; R Beyaert; G J Graham; F Y Liew
Journal:  Mucosal Immunol       Date:  2014-01-15       Impact factor: 7.313

Review 8.  Interleukin-33 and inflammatory bowel diseases: lessons from human studies.

Authors:  Tiago Nunes; Claudio Bernardazzi; Heitor S de Souza
Journal:  Mediators Inflamm       Date:  2014-02-20       Impact factor: 4.711

9.  Elevated Circulating Interleukin 33 Levels in Stable Renal Transplant Recipients at High Risk for Cardiovascular Events.

Authors:  Holly Mansell; Mahmoud Soliman; Hamdi Elmoselhi; Ahmed Shoker
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

10.  Serum Levels of IL-33 and Correlation with IL-4, IL-17A, and Hypergammaglobulinemia in Patients with Autoimmune Hepatitis.

Authors:  Ma Liang; Zhang Liwen; Zhuang Yun; Ding Yanbo; Chen Jianping
Journal:  Mediators Inflamm       Date:  2018-06-24       Impact factor: 4.711
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.